Materials and LinksReview article based on the Salvage Therapy II Workshop: 7th International Congress on Drug Therapy in HIV Infection Presentation: Workshop Presentations: Workshop Documents: |
Salvage Therapy II
Background:
There is a growing population of treatment-experienced “salvage” patients for whom there are limited or no viable treatment options left to combat HIV. The problem is worsened due to intra-class cross-resistance, quickly turning 20 approved antiretroviral drugs into just a few viable drug combinations for any given patient. Frequently, the only option is to wait for new drugs to become available; however, these will need to be new drugs with unique resistance profiles. Ideally, salvage patients must wait for at least 2 new drugs to be available for any chance of keeping HIV suppressed for a significant amount of time.
Although the “salvage status” affects a great proportion of HIV infected individuals today, and may ultimately be the fate of all HIV patients, there are very few treatment guidelines for how to use anti-HIV therapy most effectively in highly treatment-experienced patients. A clearly defined medical research agenda to effectively treat salvage patients has not been developed. The Forum for Collaborative HIV Research convened a Salvage Therapy Workshop in 1999. This workshop resulted in a greater recognition of the salvage therapy problem and the inclusion of salvage therapy in clinical research, most notably clinical trials in the drug approval process. Salvage Therapy II will bring together researchers and clinicians to review advances since the first workshop, identify current challenges, establish principles for treating salvage patients based on research to date, and establish widespread research goals for enhancing the care and survival of these patients.
Objectives:
To bring together researchers and clinicians, government representatives, community representatives, and other leaders with the goal of establishing priorities and objectives for increasing the effectiveness of medical care, the quality of life, and the survival of highly treatment-experienced (“salvage”) patients with HIV/AIDS.
To identify promising areas of basic science and clinical research that might translate into the development of treatments or the establishment of useful clinical care guidelines for the medical management of salvage patients
To facilitate initiation of research collaborations among the various participants and to establish a functioning national network of research collaborators for implementing these research priorities and objectives.
Steering Committee
Jeff Murray (Kim Struble), Steve Deeks, Lynn Smiley, Cal Cohen, Roberto Arduino, Gregg Gonsalves, Trip Gulick, Dorothy Lewis, Tom Gegeny, Veronica Miller
For further information contact:
Veronica Miller, Ph.D.(
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
)
Status:
The workshop was held on April 16-17, 2004 in Houston, TX.
Meeting Agenda
|
Topic |
Speaker/Panelists/Moderators |
|
Welcome and Introduction |
Session I
|
Topic |
Speaker/Panelists/Moderators |
|
Recap of Forum '99 Meeting |
Session II
|
Topic |
Speaker/Panelists/Moderators |
|
Clinical Research in the Salvage Setting |
Trip Gulick |
|
Overview Talk: Recent Experiences in Salvage Therapy: T20 |
|
|
Panel Discussion: Industry Perspective, Patient Perspective, Regulatory Perspective, & Clinical Research Perspective |
Miklos Salgo, Eric Lefebvre, Matt Sharp, Jeff Murray, Nathalie Morgensztejn, & Dan Kuritzkes |
Session III
|
Topic |
Speaker/Panelists/Moderators |
|
Clinical Management Issues in the Salvage Setting |
Tom Campbell |
|
Overview Talk: Salvage Therapy Today |
|
|
Panel Discussion |
Steven Deeks, Joel Gallant, Cal Cohen, & Bob Huff |
Session IV
|
Topic |
Speaker/Panelists/Moderators |
|
Do We Have New Tools? |
Richard Haubrich |
|
Overview Talk: New Drugs in the Pipeline - are the Expected Challenges Different? |
Richard Ogden |
|
Panel Discussion |
Richard Ogden, George Hanna, Nancy Chang, Jeff Murray, & Mike Youle |
Session V
|
Topic |
Speaker/Panelists/Moderators |
|
Novel Strategies in Salvage |
Ben Cheng |
|
Overview Talk: Novel Strategies for Treating/Managing Salvage or Heavily Treatment-Experienced Patients: What has Worked, What Hasn't Worked; What Haven't We Tried Yet or Need to Pursue Further, What's in the Works or Being Talked About? |
|
|
Panel Discussion |
Cal Cohen, Steven Deeks, Kim Struble, Courtney Fletcher, Martin Delaney, & Robert Arduino |
Session VI
Group Panel Discussions
|
Topic |
Speaker/Panelists/Moderators |
|
Panel 1: Integrating Salvage Research Into Existing Networks/Structures (Clinical Trial Networks, Observational Cohorts, Industry Sponsored Programs) |
Daniel Kuritkes (Leader), Roberto Arduino, Rich Arenschieldt, Cal Cohen, David Evans, Eric Lefebvre, Sandy Lehrman, Richard Ogden, Betty Slagle, & Mike Youle |
|
Panel 2: Proof of Concept Studies/Translational |
Kim Struble (Leader), Tom Campbell, Nancy Chang, Ben Cheng, Steve Deeks, Courtney Fletcher, Tom Gegeny, George Hanna, Bob Huff, Dorothy Lewis, Jennifer Newcomb-Fernandez |
|
Panel 3: Future of Salvage Therapy: Monitoring Systems for Patient Outcomes. Will the Needs Change in the Next Decade? |
Doug Ward (Leader), Ben Barnett, Tanvir Bell, Andrew Cheng, Joel Gallant, Richard Haubrich, Tim Murphy, Neil Parkin, Maria Rodriguez, Matt Sharp, Clinton White |
|
Panel 4: Regulatory Issues and Challenges in Salvage Therapy |
Roy Gulick (Leader), Lynda Dee, Martin Delaney, Stanley Lewis, Jeff Murray, Nathalie Morgensztejn, Miklos Salgo, Daniel Seekins, Nelson Vergel, & Marjorie Williams |
|
Final Discussion Round |
Veronica Miller |
Project Specific Sponsor
Tibotec
Project Co-Sponsor
The Center for AIDS: Hope & Remembrance Project
